Abstract
Molecular imaging with various biomarkers plays a significant role in the diagnostic assessment of patients with dementing disorders, by detecting functional and pathophysiologic changes in the brain. PET imaging, in particular, allows the measurements of different molecular targets, such as functional markers of neurodegeneration (glucose metabolism), markers for pathological aggregates (such as amyloid, tau and synuclein aggregates) and neuroinflammation, and also markers of several neurotransmission systems. In the current view, neurodegenerative diseases are associated with the development of pathologic changes that play a different role in disease onset and evolution, often starting long before the onset of clinically detectable impairment. Molecular imaging represents thus a unique tool to collect relevant information contributing to accurate diagnosis, treatment and response monitoring. In this article, we review the current literature focusing on the PET radiotracers used for molecular imaging in dementia.
Keywords: Dementia, biomarkers, glucose metabolism, amyloid, tau protein, synuclein, neurotransmission.
Current Radiopharmaceuticals
Title:PET Radiotracers for Molecular Imaging in Dementia
Volume: 6 Issue: 4
Author(s): Aylin Baskin, Panteleimon Giannakopoulos, Osman Ratib, Yann Seimbille, Frederic Assal, Daniela Perani and Valentina Garibotto
Affiliation:
Keywords: Dementia, biomarkers, glucose metabolism, amyloid, tau protein, synuclein, neurotransmission.
Abstract: Molecular imaging with various biomarkers plays a significant role in the diagnostic assessment of patients with dementing disorders, by detecting functional and pathophysiologic changes in the brain. PET imaging, in particular, allows the measurements of different molecular targets, such as functional markers of neurodegeneration (glucose metabolism), markers for pathological aggregates (such as amyloid, tau and synuclein aggregates) and neuroinflammation, and also markers of several neurotransmission systems. In the current view, neurodegenerative diseases are associated with the development of pathologic changes that play a different role in disease onset and evolution, often starting long before the onset of clinically detectable impairment. Molecular imaging represents thus a unique tool to collect relevant information contributing to accurate diagnosis, treatment and response monitoring. In this article, we review the current literature focusing on the PET radiotracers used for molecular imaging in dementia.
Export Options
About this article
Cite this article as:
Baskin Aylin, Giannakopoulos Panteleimon, Ratib Osman, Seimbille Yann, Assal Frederic, Perani Daniela and Garibotto Valentina, PET Radiotracers for Molecular Imaging in Dementia, Current Radiopharmaceuticals 2013; 6 (4) . https://dx.doi.org/10.2174/1874471006666131126223411
DOI https://dx.doi.org/10.2174/1874471006666131126223411 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Visuospatial Memory in Healthy Elderly, AD and MCI: A Review
Current Aging Science Peripheral Benzodiazepine Receptor (PBR) New Insight in Cell Proliferation and Cell Differentiation Review
Current Clinical Pharmacology The Role of Fatty Acids in the Regulation of Cerebral Vascular Function and Neuroprotection in Ischemia
CNS & Neurological Disorders - Drug Targets Multiple Roles of Annexin A2 in Post-Transcriptional Regulation of Gene Expressio
Current Protein & Peptide Science Exogenous Progesterone: A Potential Therapeutic Candidate in CNS Injury and Neurodegeneration
Current Medicinal Chemistry Patent Selections
Recent Patents on Drug Delivery & Formulation Immune Modulation of HIV Replication: Relevance to HIV Immuno- and Neuro-Pathogenesis
Current HIV Research Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG
Current Vascular Pharmacology Reactive Oxygen Species, Redox Signaling and Neuroinflammation in Alzheimer's Disease: The NF-κB Connection
Current Topics in Medicinal Chemistry Clinical Herbal Interactions with Conventional Drugs: From Molecules to Maladies
Current Medicinal Chemistry Cognitive Impairment in Depression
Current Psychiatry Reviews May Oxygen-Ozone Therapy Improves Cardiovascular Disorders?
Cardiovascular & Hematological Disorders-Drug Targets ACAT1 as a Therapeutic Target and its Genetic Relationship with Alzheimer's Disease
Current Alzheimer Research Modification Strategies of Lipid-Based Nanocarriers for Mucosal Drug Delivery
Current Pharmaceutical Design Neurobrucellosis: A Case Report with an Unusual Presentation
Recent Advances in Anti-Infective Drug Discovery Assembly In Vitro of Tau Protein and its Implications in Alzheimers Disease
Current Alzheimer Research Inflammatory and Neurodegenerative Pathways in Depression: A New Avenue for Antidepressant Development?
Current Medicinal Chemistry Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer,s Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
Current Alzheimer Research Genetic Contributors to Frontotemporal Lobar Degeneration: Beyond Monogenic Disease
Mini-Reviews in Medicinal Chemistry Nanotechnology: A Novel Approach for Drug Development in Health Care System
Current Nanomaterials